Synapse - Works

Results (2950)

Comprehensive genomic profiling (CGP) informs molecular diagnosis, prognosis, and therapeutic decision-making for patients with angioimmunoblastic T-cell lymphoma (AITL)

Meeting Abstract

Morley, S.; He, J.; Intlekofer, A. M.; Bailey, M.; Nahas, M.; Heilmann, A.; Chudnovsky, Y.; Fabrizio, D.; Ali, S. M.; Lipson, D.; more...
Blood (2017)

Fulltext@MSK | Save

Costs and in-hospital mortality rates in autologous stem cell transplant for multiple myeloma: An analysis of the Nationwide Inpatient Sample (NIS) Database

Meeting Abstract

Liu, Y.; Han, H.; Wei, X.; Wang, Q.; He, J.; Shah, G. L.; Giralt, S. A.; Landgren, O.; Lesokhin, A.
Blood (2017)

Fulltext@MSK | Save

MRD response-driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone

Meeting Abstract

Korde, N.; Mailankody, S.; Smith, E. L.; Lendvai, N.; Hassoun, H.; Lesokhin, A.; Hultcrantz, M.; Chung, D. J.; Shah, G. L.; Koehne, G.; more...
Blood (2017)

Fulltext@MSK | Save

B-cell maturation antigen is exclusively expressed in a wide range of B-cell and plasma cell neoplasm and in a potential therapeutic target for BCMA directed therapies

Meeting Abstract

Khattar, P.; Pichardo, J.; Jungbluth, A.; Gao, Q.; Smith, E. L.; Roshal, M.; Dogan, A.
Blood (2017)

Fulltext@MSK | Save

Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) after multiple myeloma: Assessment of risk factors

Meeting Abstract

Jonsdottir, G.; Bjorkholm, M.; Turesson, I.; Hultcrantz, M.; Porwit, A.; Jethava, Y.; Landgren, O.; Kristinsson, S. Y.
Blood (2017)

Fulltext@MSK | Save

Genomic characteristics clinical phenotype and disease course of TP53 mutated diffuse large B cell lymphoma at diagnosis and relapse

Meeting Abstract

Joffe, E.; Batlevi, C. L.; Intlekofer, A. M.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Noy, A.; Straus, D. J.; Portlock, C. S.; Gerecitano, J.; more...
Blood (2017)

Fulltext@MSK | Save

Daratumumab monotherapy for patients with intermediate or high-risk smoldering multiple myeloma (SMM): Centaurus, a randomized, open-label, multicenter phase 2 study

Meeting Abstract

Hofmeister, C. C.; Chari, A.; Cohen, Y.; Spencer, A.; Voorhees, P. M.; Estell, J.; Venner, C. P.; Sandhu, I.; Jenner, M. W.; Williams, C.; more...
Blood (2017)

Fulltext@MSK | Save

Development of JCARH125: Optimization of a fully human anti-BCMA CAR for use in the treatment of multiple myeloma

Meeting Abstract

Harrington, K.; Wu, R.; Hauskins, C.; Amin, R.; Long, T.; Chen, A.; Rahardjo, A.; Thayer, C.; Navvaro, G.; Myers, M.; more...
Blood (2017)

Fulltext@MSK | Save

Generation and application of T-cell lymphoma patient derived tumor xenograft models

Meeting Abstract

Fiore, D.; Wang, X.; Khodos, I.; Di Giacomo, F.; Gaudiano, M.; Phillip, J. M.; Wang, R.; Yang, Z.; Ginsberg, M.; Intlekofer, A. M.; more...
Blood (2017)

Fulltext@MSK | Save

A phase 2 study of actinium-225 ((225)Ac)-lintuzumab in older patients with previously untreated acute myeloid leukemia (AML) unfit for intensive chemotherapy

Meeting Abstract

Finn, L. E.; Levy, M.; Orozco, J. J.; Park, J. H.; Atallah, E.; Craig, M.; Perl, A. E.; Scheinberg, D. A.; Cicic, D.; Bergonio, G. R.; more...
Blood (2017)

Fulltext@MSK | Save